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Abstract
Background: Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late
recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify
clinical factors associated with the late recurrence.
Methods: We reviewed our database of ER-positive patients who had received operations between 1996 and
2006 in two institutions. We selected 444 who had completed 5-year tamoxifen and were disease-free up to
10 years after the operation. Patients who had received aromatase inhibitors with any regimens were excluded.
As a late recurrence group, 139 patients were identified who had completed 5-year tamoxifen, but had recurrence
afterwards. Among them, 61 had local/contralateral breast recurrence and 78 had distant metastasis. The median
follow-up was 9.7 years. Clinicopathological factors at the time of initial operation, such as age, menopausal status,
progesterone receptor expression, HER2 status, tumor grade and Ki-67, were compared between the disease-free
group and the late recurrence group.
Results: In a univariate analysis, tumor size (>2 cm), lymph node metastasis and high histologic grade were significantly
associated with late recurrences (p < 0.05). In a multivariate analysis, only axillary lymph node metastasis was significant
(p < 0.001). Late distant metastasis was significantly associated with tumor size and axillary lymph node metastasis
(p = 0.038, p < 0.001,respectively). Late local/contralateral breast recurrence was associated with axillary lymph
node metastasis (p = 0.042).
Conclusions: Our data showed axillary lymph node metastasis at initial operation was the only risk factor of late
recurrence after completion of tamoxifen for 5 years. Our results can be helpful in making decisions to use extended
tamoxifen beyond 5 years.
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Background
The treatment of breast cancer has developed remarkably
in recent decades, especially in hormone receptor-positive
subtype breast cancer [1–7]. Although adjuvant endocrine
therapy was highly effective and could reduce recurrence
and the mortality of hormone receptor-positive patients,
the long-term follow-up data showed that there was a sus-
tained hazard of recurrence even after the completion of
5 years of adjuvant endocrine therapy [2, 6, 8–10]. There-
fore, strategies to reduce late recurrence in this subtype of
breast cancer have been intensively studied [11–15].
For the past few decades, 5-year use of tamoxifen has
been a standard adjuvant endocrine therapy with a large
survival gain and minimal adverse effects [8, 16–19].
Studies have shown that tamoxifen therapy has a carryover
effect, which results in the reduction in recurrence well
after treatment has stopped [9, 17, 20]. Some earlier studies
suggested that use of tamoxifen for more than 5 years has
few benefits and increases side effects [17, 19, 21]. How-
ever, two recent large clinical trials, ATLAS (Adjuvant
Tamoxifen: Longer Against Shorter) and aTTom (adjuvant
Tamoxifen–To Offer More?) have shown that continuing
tamoxifen therapy beyond 5 years reduces recurrence and
death from breast cancer over the following years [22, 23].
Accordingly, the new ASCO guidelines recommend a adju-
vant hormonal therapy of women who have hormone re-
ceptor–positive breast cancer for a duration of up to
10 years rather than 5 years [24]. The next challenge is to
determine which patients will benefit from this long-term
treatment, because its side effects, such as menopausal
symptoms and the risk of endometrial cancer, are consider-
able [11, 21].
We analyzed the clinicopathological features at the
time of surgery of patients who had late recurrence
compared with those of patients who were long-term
disease-free. We found predictive factors, which will
help clinics to select patients who will benefit more from
extended adjuvant tamoxifen use for more than 5 years.
Methods
Study subjects
We reviewed the data of 3920 patients with estrogen
receptor (ER)-positive primary invasive breast cancer
who underwent curative surgery in both Seoul National
University Hospital and National cancer center from
January 1996 to September 2006. We identified 2154
patients who were disease-free when they had finished
5-year adjuvant tamoxifen therapy. Patients who had
received aromatase inhibitors at any time during tamoxi-
fen therapy were excluded. Additionally, patients who had
received extended endocrine therapy with tamoxifen or
aromatase inhibitors for a total duration of more than
5 years were excluded. For the disease-free group, patients
who were lost before 10 years of follow-up from the initial
surgery were excluded. Late recurrence was defined as any
locoregional (in the ipsilateral/contralateral breast, chest
wall, or regional lymph nodes including micro-, macro-
metastasis and isolated tumor cells in axilla) or distant
Fig. 1 Flowchart of patient selection
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relapse on the image study or pathologic confirmation
occurring after the completion of 5-year adjuvant tamoxi-
fen therapy. Finally, a total of 583 patients were enrolled
in this study. A total of 444 were placed in the disease-free
group, and 139 were placed in the late recurrence group
(Fig. 1). This study was approved by the Institutional
Review Board of Seoul National University Hospital
(IRB number: 1409-155-616).
IHC staining and interpretation
This method was previously used in a published study
[25]. The samples were immunostained with the following
antibodies according to the manufacturers' instructions:
Anti-ER (1:100; 1D5; Dako, Glostrup, Denmark), anti-
progesterone receptor (PgR) (1:100; 636; Dako), and
anti-HER2 (1:200; A0485; Dako). The IHC staining was
scored and confirmed by two pathologists who were
blinded to the clinical information. Positive ER and PgR
expression were defined as nuclear staining in 10 % or
more of tumor cells. The HER2 membranous staining was
scored on a scale of 0 to 3+ according to the HercepTest
protocol. For tissue samples with a HER2 staining score of
2+, additional HER2 FISH testing was performed. HER2
status was considered positive when the IHC score was
3+ or the gene copy ratio of HER2/CEP17 by FISH was
2.0 or higher.
Statistical analysis
Disease-free survival (DFS) was defined as the length of
time after surgery for primary breast cancer to the
earliest report of any locoregional or distant recur-
rence. Pearson’s chi-square test was used to analyze the
association between clinicopathological factors and late
recurrence. Logistic regression analysis was used for
the multivariate analysis of significant variables in the
univariate chi-square tests, such as age, menopausal
status, tumor size (e.g., ≤2 cm or >2 cm), metastatic
axillary lymph nodes (positive or negative), tumor grade
Table 1 Clinicopathologic characteristics of study subjects




Pre-menopause 411 (70.5 %)
Post-menopause 148 (25.4)
Unknown 24 (4.1 %)
Tumor size
≤2 cm 333 (57.1 %)
>2 cm 250 (42.9 %)
Axillary nodal status
Node positive
(micro- & macro-metastasis/isolated tumor cell)
223 (38.3 %)
Node negative 360 (61.7 %)
AJCC stage
I 247 (42.4 %)
II 272 (46.7 %)
III 64 (10.9 %)
Histologic type
Ductal carcinoma 522 (89.5 %)
Lobular carcinoma 17 (2.9 %)
Others 44 (7.6 %)
Progesterone receptor
Positive 383 (65.7 %)
Negative 198 (34.0 %)
Unknown 2 (0.3 %)
HER2
Positive 86 (14.7 %)
Negative 328 (56.3 %)
Unknown 169 (29 %)
Nottingham Histologic Score
1 78 (13.4 %)
2 314 (53.9 %)
3 122 (20.9 %)
Unknown 69 (11.8 %)
Ki-67
High (≥10 %, or ≥14 %)a 120 (20.6 %)
Low (<10 %, or <14 %)a 425 (72.9 %)
Unkonwn 38 (6.5 %)
Surgery-Breast
Mastectomy 308 (52.8 %)
Breast conservationb 275 (47.2 %)
Table 1 Clinicopathologic characteristics of study subjects
(Continued)
Surgery-Axilla
SLNBxc Only 19 (3.3 %)
ALNDd 557 (95.5 %)
Others 7 (1.2 %)
Adjuvant treatment
Radiotherapy 197 (33.8 %)
Chemotherapy 307 (52.7 %)
aThe cutoff values of Ki-67 are 14 % in NCC and 10 % in SNUH [26]
bAll patients obtained clear resection margin
cSLNBx., Sentinel lymph node biopsy
dALND, axillary lymph node dissection
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(Nottingham Histologic Score 1, 2, or 3), human epi-
dermal growth factor receptor 2 (HER2) status (positive
or negative), progesterone receptor expression (positive
or negative), and Ki67 level (high (≥10 % in SNUH, ≥14 %
in NCC) or low (<10 % in SNUH, <14 % in NCC)) [26].
Kaplan–Meier plots were used to show the survival results
and comparison between the groups. All statistical
analyses were performed using SPSS Version 19.0 soft-
ware. All p values were two-sided, and p < 0.05 was
considered significant.
Results
Table 1 summarizes the clinicopathologic characteristics
of this study population. The mean age of patients was
45.5 years old. The mean follow-up period was 10.6 years
in disease-free patients, and the mean disease-free time
was 8.0 years (ranging from 5.1 to 14.3 years) in the late
recurrence group. A total of 444 patients of 583 (76.2 %)
had disease-free status by the end of the follow-up date,
at least 10 years after diagnosis. A total of 139 patients
(23.8 %) experienced local or distant recurrences after
completion of adjuvant tamoxifen therapy for 5 years.
Recurrences occurred between 5 to 10 years after the
operation in 118 (84.9 %) women and after 10 years in
21(15.1 %) patients. A total of 61 patients experienced
locoregional or contralateral breast recurrence, and 78
experienced distant metastasis (Table 2).
In the univariate analysis, large tumor size (>2 cm),
positive axillary lymph node metastasis, and high histo-
logic grade were significantly related to late recurrence
(p = 0.002, p < 0.001, and p = 0.018, respectively). In the
multivariate logistic regression analysis, only axillary lymph
node metastasis at the time of initial operation was signifi-
cantly associated with late recurrence compared with the
disease-free group (p < 0.001) (Table 3). In the subgroup
analysis, distant metastasis in the late recurrence group
was significantly associated with axillary lymph node
metastasis and large tumor size (p < 0.001, p = 0.038,
respectively), and local recurrence or contralateral breast
recurrence was associated with only axillary lymph node
metastasis (p = 0.042) (Table 4). Figure 2 shows Kaplan–
Meier curves for DFS according to lymph node status.
Patients who were lymph node-positive at the time of
initial operation had significantly worse survival rates after
the completion of 5-year adjuvant tamoxifen therapy
(log rank p-value <0.001).
Discussion
Although there have been great advances in the survival
outcomes of patients with ER-positive breast cancer, many
patients still experience late recurrence [1, 2]. The use of
extended endocrine therapy for more than 5 years in order
to reduce late recurrence is controversial [11, 27]. Due to
the publication of positive results from large randomized
trials that have shown the benefits of 10-year tamoxifen
therapy, new ASCO guidelines recommend a total of
10 years of adjuvant hormonal therapy for all ER-positive
patients [22, 24]. However, it is not clear whether all ER-
positive breast cancer patients should be offered extended
endocrine treatment. The important question is which
patients would be at a higher risk of recurrence after
5 years of endocrine therapy and which would benefit
from extended therapy.
Table 2 Recurrence type in 139 patients of late recurrence





Axillary lymph node 2
Distant metastasis 78
Visceral metastasis (≥1 organ)a 48
Non-visceral metastasis 30
Bone metastasis only 26
Multiple metastasis in non-visceral oraganb 4
aLung, liver, brain metastasis with or without bone metastasis
bBone metastasis with lymph node metastasis such as internal mammary LN
or subclavian LN
Table 3 Univariate (chi-square) and multivariate (logistic
regression) analysis for clinicopathological features associated




P value Odds ratio 95 % CI P
value





(>2 cm vs ≤2 cm)
0.002 1.297 0.762–2.207 0.338
ALNa metastasis
(yes vs no)








(Gr III vs Gr I or II)
0.018 1.396 0.786–2.479 0.256







aALN axillary lymph node
bPgR progesterone
cThe cutoff values of Ki-67 are 14 % in NCC and 10 % in SNUH [26]
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We demonstrated an association between axillary lymph
node metastasis at the time of initial operation and late re-
currence in patients who completed 5-year tamoxifen
therapy. This result can be helpful for clinics when con-
sidering the extended use of tamoxifen beyond 5 years.
Doctors might be able to strongly recommend this
therapy when the patient is lymph node-positive at the
time of initial surgery. Several previous reports have
shown similar results [12, 28, 29]. A meta-analysis con-
ducted by Al-Mubarak et al. on extended adjuvant
endocrine therapy for early breast cancer showed that
the apparent benefits were observed only among pa-
tients with lymph node-positive disease, and the abso-
lute risk reduction during 10 years of follow-up was
almost doubled in lymph node-positive patients [30].
In this study, it is notable that tumor biological factors
known as predictors of early recurrence, such as Ki67 or
HER2, were not predictors of late recurrence. This sug-
gests the necessity of developing a new biomarker with
good prediction accuracy for late recurrence in ER-
positive disease. Recently, multigene assays have shown
promising results in the prediction of late recurrence
[29, 31–34]. Sgroi et al. compared the prognostic effica-
cies of the breast-cancer index (BCI) assay, 21-gene
recurrence score (Oncotype DX), and an immunohisto-
chemical prognostic model (IHC4). As a result, BCI assay
provided significant prognostic information for both early
and late distant recurrence [31]. Another multigene-based
assay, the EndoPredict test combined with nodal status
and tumor size (EPclin), reliably identified a subgroup of
patients who showed excellent long-term prognoses after
5 years of endocrine therapy [32]. In a recent large com-
bined analysis of TranATAC and ABCSG8 studies, the
risk of recurrence(ROR) score of the PAM50 added
clinically meaningful prognostic information to the
Clinical Treatment Score in all patients and subgroups
in the late follow-up period. They suggested that the ROR
score could be helpful for separating into risk groups pa-
tients who could be spared or potentially benefit from ex-
tended hormonal therapy beyond 5 years of treatment [35].
In our study, the small number of late recurrence events
was a weakness. This limitation is due to the fact that the
study was performed in just two institution. It was also be-
cause we excluded patients whose follow-up duration was
not sufficient and who took aromatase inhibitors in any
sequence with adjuvant tamoxifen. Another limitation of
our study was considerable missing data on HER2 status.
Before the adjuvant trastuzumab era, HER2 status was de-
termined by IHC alone. We regarded HER2 as unknown
when the HER2 IHC score was 2+ and HER2 FISH data
was not available for the patient. Moreover, the absence of
information on the degree of ER expression known to be
directly associated with the benefits of tamoxifen [8] was
another limitation of our study.
Conclusions
Our data showed that axillary lymph node metastasis at
the time of initial operation was significantly associated
with late recurrence after completion of 5-year tamoxifen
therapy. This result would be useful for making decisions
regarding using extended tamoxifen therapy for more than
5 years and when multi-gene assays are not available.
Additional file
Additional file 1: This file includes raw-data of 583 patients’ characteristics
and survival. (XLSX 40 kb)
Table 4 Subgroup analysis for associated factors with local or distant metastasis respectively
Variables Local + contralateral breast recurrence Distant metastasis
N = 61 N = 78
Odds Ratio (95 % CI) P value Odds Ratio (95 % CI) P value
Age(<50 vs ≥50) 0.970 (0.938 ~ 1.004) 0.084 0.984 (0.955 ~ 1.013) 0.282
Tumor size (>2 cm vs ≤ 2 cm) 0.834 (0.467 ~ 1.489) 0.539 1.767 (1.033 ~ 3.023) 0.038
ALNa metastasis (Yes vs No) 1.817 (1.022 ~ 3.229) 0.042 4.274 (2.470-7.395) <0.001
aALN axillary lymph node
Fig. 2 Kaplan–Meier analysis of disease-free survival according to
lymph node status at initial operation
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